{"id":838247,"date":"2025-04-16T16:14:15","date_gmt":"2025-04-16T20:14:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/"},"modified":"2025-04-16T16:14:15","modified_gmt":"2025-04-16T20:14:15","slug":"viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/","title":{"rendered":"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <b><br \/>\n          <i>Conference Call Scheduled for <span class=\"xn-chron\">Wednesday, April 23<\/span> at <span class=\"xn-chron\">4:30 p.m. Eastern Time<\/span><\/i><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 16, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on <span class=\"xn-chron\">Wednesday, April 23, 2025<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg\" title=\"Viking Therapeutics (PRNewsfoto\/Viking Therapeutics, Inc.)\" alt=\"Viking Therapeutics (PRNewsfoto\/Viking Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The company will host a conference call to discuss financial results and general corporate updates beginning at <span class=\"xn-chron\">4:30 p.m. Eastern Time on Wednesday<\/span>, April 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until <span class=\"xn-chron\">April 30, 2025<\/span>, by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S. and entering replay access code #8779272.\u00a0Those interested in listening to the conference call live via the internet may do so by visiting the Webcasts page of Viking&#8217;s website at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4406133-1&amp;h=4284174105&amp;u=http%3A%2F%2Fir.vikingtherapeutics.com%2Fwebcasts&amp;a=http%3A%2F%2Fir.vikingtherapeutics.com%2Fwebcasts\" target=\"_blank\" rel=\"nofollow\">http:\/\/ir.vikingtherapeutics.com\/webcasts<\/a>. An archive of the webcast will also be available on the Webcasts page of the company&#8217;s website for 30 days.<\/p>\n<p>\n        <b>About Viking Therapeutics, Inc.\u00a0<\/b>\n      <\/p>\n<p>Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.\u00a0Viking&#8217;s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients&#8217; lives.\u00a0Viking&#8217;s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (<span>GLP-1<\/span>) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase\u00a02b\u00a0study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.\u00a0In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.\u00a0The company&#8217;s newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.\u00a0 In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).\u00a0 In a Phase\u00a01b\u00a0clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.<\/p>\n<p>For more information about Viking Therapeutics, please visit\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4406133-1&amp;h=3666172532&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4197323-1%26h%3D4201129706%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4124488-1%2526h%253D3719708903%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3866590-1%252526h%25253D4076357968%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3821369-1%25252526h%2525253D1599847740%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3586345-1%2525252526h%252525253D65010134%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3117978-1%252525252526h%25252525253D1140731627%252525252526u%25252525253Dhttp%2525252525253A%2525252525252F%2525252525252Fwww.vikingtherapeutics.com%2525252525252F%252525252526a%25252525253Dwww.vikingtherapeutics.com%2525252526a%252525253Dwww.vikingtherapeutics.com%25252526a%2525253Dwww.vikingtherapeutics.com%252526a%25253Dwww.vikingtherapeutics.com%2526a%253Dwww.vikingtherapeutics.com%26a%3Dwww.vikingtherapeutics.com&amp;a=www.vikingtherapeutics.com\" target=\"_blank\" rel=\"nofollow\">www.vikingtherapeutics.com<\/a>.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA65476&amp;sd=2025-04-16\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025-302429383.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025-302429383.html<\/a><\/p>\n<p>SOURCE  Viking Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA65476&amp;Transmission_Id=202504161605PR_NEWS_USPR_____LA65476&amp;DateId=20250416\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time SAN DIEGO , April 16, 2025 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-838247","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time SAN DIEGO , April 16, 2025 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, &hellip; Continue reading &quot;Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T20:14:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025\",\"datePublished\":\"2025-04-16T20:14:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/\"},\"wordCount\":546,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/\",\"name\":\"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"datePublished\":\"2025-04-16T20:14:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/273590\\\/viking_9_15_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/","og_locale":"en_US","og_type":"article","og_title":"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Market Newsdesk","og_description":"PR Newswire Conference Call Scheduled for Wednesday, April 23 at 4:30 p.m. Eastern Time SAN DIEGO , April 16, 2025 \/PRNewswire\/ &#8212;\u00a0Viking Therapeutics, Inc. (&#8220;Viking&#8221;) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, April 23, 2025. To participate on the conference call, please dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. In addition, following the completion of the call, &hellip; Continue reading \"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-16T20:14:15+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025","datePublished":"2025-04-16T20:14:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/"},"wordCount":546,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/","name":"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","datePublished":"2025-04-16T20:14:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/273590\/viking_9_15_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viking-therapeutics-to-report-financial-results-for-first-quarter-2025-on-april-23-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/838247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=838247"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/838247\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=838247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=838247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=838247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}